Zentalis Pharmaceuticals Llc

Yahoo Finance • 17 days ago

Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum

(RTTNews) - Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names ral... Full story

Yahoo Finance • 24 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian c... Full story

Yahoo Finance • 29 days ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian ca... Full story

Yahoo Finance • last month

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

SAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian ca... Full story

Yahoo Finance • 3 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian ca... Full story

Yahoo Finance • 5 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian c... Full story

Yahoo Finance • 6 months ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthe... Full story

Yahoo Finance • 6 months ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the po... Full story

Yahoo Finance • 6 months ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~3... Full story

Yahoo Finance • 8 months ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8... Full story

Yahoo Finance • 2 years ago

Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares

In the realm of stock market movements, insider trading activity is often a significant indicator that investors monitor to gauge the confidence of management and key stakeholders in the company's future. A recent transaction by David John... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) (“Zentalis”) on behalf of the company’s investors. Since September 2023, shares of Zentalis... Full story

Yahoo Finance • 2 years ago

Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen

Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, N... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Continues Investigation into Zentalis Pharmaceuticals, Inc.; Urges Zentalis Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determin... Full story

Yahoo Finance • 2 years ago

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gyn... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Zentalis Pharmaceuticals, Inc.; Urges Zentalis Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determin... Full story

Yahoo Finance • 2 years ago

Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

NEW YORK and SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics target... Full story

Yahoo Finance • 2 years ago

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

NEW YORK and SAN DIEGO, June 15, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeti... Full story

Yahoo Finance • 2 years ago

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib + chemotherapy clinical data in ovaria... Full story

Yahoo Finance • 2 years ago

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announ... Full story